

## Op2Lysis to acquire license from *CARLINA Technologies* to secure and strengthen O2L-001 IP.

**Boulogne-Billancourt, France, June 11<sup>th</sup>, 2020** – Op2Lysis, the biotech company dedicated to the development of the first medical treatment of hemorrhagic stroke, the most disabling form of stroke, which affects more than 1.5 million people worldwide every year, announced the signature of a license agreement with CARLINA Technologies for exploiting its PEPTIDOTS™ technology. Optimized plasminogen activator (OptPA) is nanoformulated with this PEPTIDOTS™ technology to produce O2L-001, the next generation of thrombolytic agent that allows faster and stronger thrombolysis with an increased safety profile for hematoma drainage in patients with intracerebral hemorrhage (ICH). O2L-001 drug product opens the opportunity to treat efficiently ICH patients with a unique injection after microinvasive surgery to place a catheter for local delivery of the product, a surgical procedure mastered by all neurosurgeons worldwide.

*"We observed very impressive results with O2L-001, our OptPA nanoformulated using the PEPTIDOTS™ technology. Using a state of art human hematoma model, O2L-001 was able to completely liquefy hematoma in only 9 hours where standard thrombolytic therapy achieved 60-70% lysis. This agreement is a major step forward to securing the exploitation of our technology and to attract new investors to progress in our preclinical program and initiate our clinical trial within the next 18 months."*, commented Christophe Gaudin, CEO of Op2Lysis.

The agreement is an engagement between the two parties to guaranty support from CARLINA Technologies and ensure GMP production of a high-quality product to meet the FDA and EMA requirements.

### **About Op2Lysis – [www.op2lysis.com](http://www.op2lysis.com)**



Op2Lysis is a biotech company dedicated to the development of the first medical treatment of hemorrhagic stroke, the most disabling form of stroke. Op2Lysis aims at becoming a major player in research and development for the management and treatment of stroke and is engaged in collaborations to develop new efficient formulations of thrombolytics for stroke patient. Christophe Gaudin and Jérôme Parcq are the co-founders of Op2Lysis. Christophe's track record, as a MD specialist with a successful drug development experience (international registration), including anti-thrombotic blockbusters for ischemic diseases, is a perfect fit to the purpose of the proposed development structure. Jérôme's experience is complementary, as a PhD with a focused background in stroke and neurovascular research. He has multidisciplinary skills highly compatible with innovative entrepreneurship and is a co-inventor of OptPA.

### **About CARLINA Technologies – [www.carlinatech.com](http://www.carlinatech.com)**

CARLINA Technologies is a nanomedicine development company using its innovative patented encapsulation platforms. The company's proprietary controlled-delivery technologies are applicable to a wide range of medicines including small molecules, proteins and peptides, and nucleic acid-based

therapeutics. CARLINA Technologies develops nanomedicines for both human and animal health with focuses on improved treatments of chronic diseases including diabetes and cancer. CARLINA Technologies also provides its drug delivery technology platforms and know-how to the pharmaceutical and veterinary industries to improve both the efficacy and the safety of their proprietary molecules through its CRO activity.



**Christophe Gaudin, M.D.**  
*Founder, CEO*



**Jerome Parcq, Ph.D.**  
*Founder, CSO*

---

*Op2Lysis* acquiert un portefeuille de licence de CARLINA Technologies pour sécuriser et renforcer sa propriété intellectuelle.